We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$148M
AUM Growth
+$11.9M
Cap. Flow
-$3.01M
Cap. Flow %
-2.04%
Top 10 Hldgs %
61.6%
Holding
48
New
13
Increased
13
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$4.95M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$4.34M
3
CLNN icon
Clene
CLNN
+$4.14M
4
IMA
ImageneBio Inc
IMA
+$3.33M
5
IMVT icon
Immunovant
IMVT
+$2.64M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$5.26M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.26M
3
BLU
BELLUS Health Inc.
BLU
+$4.55M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$4.52M
5
CBAY
Cymabay Therapeutics
CBAY
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 2.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
26
DELISTED
HilleVax
HLVX
$1.08M 0.73%
63,078
+56,414
+847% +$874K
MORF
27
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1M 0.68%
+17,500
New +$914K
ARWR icon
28
Arrowhead Research
ARWR
$12.1B
$981K 0.66%
+27,500
New +$948K
OLMA icon
29
Olema Pharmaceuticals
OLMA
$985M
$956K 0.65%
+105,814
New +$639K
BMEA icon
30
Biomea Fusion
BMEA
$86.8M
$878K 0.59%
+40,000
New +$1.25M
DYN icon
31
Dyne Therapeutics
DYN
$4.71B
$821K 0.56%
+73,000
New +$861K
RZLT icon
32
Rezolute
RZLT
$473M
$739K 0.5%
373,400
+7,196
+2% +$14.8K
SVRA icon
33
Savara
SVRA
$1.09B
$633K 0.43%
198,139
-892
-0.4% -$2.1K
KRON
34
DELISTED
Kronos Bio
KRON
$542K 0.37%
+315,000
New +$500K
NUVB.WS
35
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$15K 0.01%
90,832
– –
FDMT icon
36
4D Molecular Therapeutics
FDMT
$527M
– –
-104,753
Closed -$1.8M
IOVA icon
37
Iovance Biotherapeutics
IOVA
$1.93B
– –
-153,639
Closed -$939K
KROS icon
38
Keros Therapeutics
KROS
$200M
– –
-3,575
Closed -$153K
MRSN
39
DELISTED
Mersana Therapeutics
MRSN
– –
-2,400
Closed -$247K
PMVP icon
40
PMV Pharmaceuticals
PMVP
$59.7M
– –
-154,471
Closed -$737K
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.68B
– –
-32,770
Closed -$4.52M
UTHR icon
42
United Therapeutics
UTHR
$25.7B
– –
-23,500
Closed -$5.26M
VKTX icon
43
Viking Therapeutics
VKTX
$3.8B
– –
-14,000
Closed -$233K
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-5,000
Closed -$31.3K
BLU
45
DELISTED
BELLUS Health Inc.
BLU
– –
-632,500
Closed -$4.55M
HZNP
46
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-6,000
Closed -$655K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Acuta Capital Partners held 48 positions worth $148M, up 8.7% from $136M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners's Q2 2023 filing shows 13 new, 13 increased, 7 reduced and 13 closed positions. Its largest new stake was Disc Medicine: 139,500 shares worth $6.19M. The largest sale was United Therapeutics, an estimated $5.26M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Consumer Staples.

  • Acuta Capital Partners's largest Q2 2023 buy was Disc Medicine: 139,500 shares worth $6.19M.
  • Acuta Capital Partners added most to Kura Oncology in Q2 2023, an estimated $1.7M increase.
  • Acuta Capital Partners's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $5.26M.
  • Acuta Capital Partners fully exited United Therapeutics in Q2 2023, selling an estimated $5.26M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $148M portfolio in Q2 2023.
  • Acuta Capital Partners opened 13 new positions and closed 13 in Q2 2023.
  • Acuta Capital Partners's portfolio value rose 8.7% quarter-over-quarter to $148M.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.